Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia

New England Journal of Medicine

Volumn 376, Issue 9, 2017, Pages 836-847

  Kantarjian, Hagop ^a   Stein, Anthony ^b   Gökbuget, Nicola ^d   Fielding, Adele K ^h   Schuh, Andre C ⁱ   Ribera, Josep Maria ^k   Wei, Andrew ⁿ   Dombret, Hervé ^o   Foà, Robin ^q   Bassan, Renato ^r   Arslan, Önder ^t   Sanz, Miguel A ^l,m   Bergeron, Julie ^j   Demirkan, Fatih ^u   Lech Maranda, Ewa ^v   Rambaldi, Alessandro ^s   Thomas, Xavier ^p   Horst, Heinz August ^e   Brüggemann, Monika ^e   Klapper, Wolfram ^f   Wood, Brent L ^w   Fleishman, Alex ^c   Nagorsen, Dirk ^c   Holland, Christopher ^c   Zimmerman, Zachary ^c   Topp, Max S ^g   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c AMGEN INC   (United States)

^d GOETHE UNIVERSITY   (Germany)

^e Medical Department II   (Germany)

^f UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h UNIVERSITY COLLEGE LONDON   (United Kingdom)

ⁱ PRINCESS MARGARET HOSPITAL   (Canada)

^j MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^k HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^l HOSPITAL UNIVERSITARIO LA FE   (Spain)

^m Autonomous University of Madrid Instituto de Investigación Hospital Universitario La Paz   (Spain)

ⁿ MONASH UNIVERSITY   (Australia)

^o UNIVERSITÉ PARIS DIDEROT   (France)

^p CENTRE HOSPITALIER LYON SUD   (France)

^q SAPIENZA UNIVERSITY OF ROME   (Italy)

^r OSPEDALE DELL'ANGELO   (Italy)

^s UNIVERSITY OF MILAN   (Italy)

^t ANKARA UNIVERSITY   (Turkey)

^u DOKUZ EYLUL UNIVERSITY   (Turkey)

^v MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

^w UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BLINATUMOMAB; CLOFARABINE; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; METHOTREXATE; BISPECIFIC ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BACTEREMIA; CANCER CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DRUG MEGADOSE; DRUG WITHDRAWAL; EVENT FREE SURVIVAL; FEMALE; HUMAN; HYPERTRANSAMINASEMIA; INFECTION; INFUSION RELATED REACTION; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROLOGIC DISEASE; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; THROMBOCYTE COUNT; ADOLESCENT; ALLOTRANSPLANTATION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPARATIVE STUDY; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, BISPECIFIC; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; SEPSIS; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS; YOUNG ADULT;

EID: 85014771892     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1609783     Document Type: Article

References (40)

1. Jabbour E, O'Brien S, Konopleva M, Kantarjian H. New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia. Cancer 2015; 121: 2517-28.
2. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol 2011; 29: 532-43.
3. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer 2004; 101: 2788-801.
4. Gokbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am 2000; 14: 1307-25.
5. Tavernier E, Boiron JM, Huguet F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 2007; 21: 1907-14.
6. Oriol A, Vives S, Hernandez-Rivas JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 2010; 95: 589-96.
7. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 1999; 86: 1216-30.
8. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010; 116: 5568-74.
9. O'Brien S, Thomas D, Ravandi F, et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113: 3186-91.
10. Gokbuget N, Stanze D, Beck J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120: 2032-41.
11. Gokbuget N, Hoelzer D. Salvage therapy of adult acute lymphoblastic leukemia. In: Faderl S, Kantarjian H, eds. Leukemias: principles and practice of therapy. Oxford, United Kingdom: Wiley-Blackwell, 2011: 217-27.
12. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 2007; 109: 944-50.
13. Raponi S, De Propris MS, Intoppa S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 2011; 52: 1098-107.
14. Loffler A, Gruen M, Wuchter C, et al. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct. Leukemia 2003; 17: 900-9.
15. Dreier T, Lorenczewski G, Brandl C, et al. Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer 2002; 100: 690-7.
16. Hoffmann P, Hofmeister R, Brischwein K, et al. Serial killing of tumor cells by cytotoxic T cells redirected with a CD19-/CD3-bispecific single-chain antibody construct. Int J Cancer 2005; 115: 98-104.
17. Topp MS, Gokbuget N, Zugmaier G, et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-40.
18. Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 2015; 16: 57-66.
19. Bruggemann M, Schrauder A, Raff T, et al. Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 2010; 24: 521-35.
20. Borowitz MJ, Wood BL, Devidas M, et al. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232. Blood 2015; 126: 964-71.
21. O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics 1979; 35: 549-56.
22. Lan KKG, DeMets DL. Discrete sequential boundaries for clinical trials. Biometrika 1983; 70: 659-63.
23. Topp M, Zimmerman Z, Cannell P, et al. Health-related quality of life (HRQoL) of blinatumomab versus standard of care (SOC) chemotherapy in patients with relapsed or refractory Philadelphia negative B-cell precursor acute lymphoblastic leukemia in a randomized, open-label phase 3 study (TOWER). Blood 2016; 128: 222. abstract.
24. Jabbour E, O'Brien S, Ravandi F, Kantarjian H. Monoclonal antibodies in acute lymphoblastic leukemia. Blood 2015; 125: 4010-6.
25. Hoelzer D, Gokbuget N. Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 2012; 26: 25-32.
26. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol 2012; 30: 3876-83.
27. Thomas DA, O'Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood 2009; 113: 6330-7.
28. Thomas DA, Faderl S, O'Brien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106: 1569-80.
29. Thomas DA, O'Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol 2010; 28: 3880-9.
30. Ribrag V, Koscielny S, Bosq J, et al. Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet 2016; 387: 2402-11.
31. Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med 2016; 375: 1044-53.
32. Jabbour E, Kantarjian H. Chemoimmunotherapy as a new standard of care for Burkitt leukaemia/lymphoma. Lancet 2016; 387: 2360-1.
33. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012; 13: 403-11.
34. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer 2013; 119: 2728-36.
35. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 2016; 375: 740-53.
36. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-17.
37. Davila ML, Riviere I, Wang X, et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014; 6: 224ra25.
38. Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet 2015; 385: 517-28.
39. Gokbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood 2012; 120: 1868-76.
40. Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: A confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTER) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia (ALL). Blood 2014; 124: 379. abstract.